University of Oxford Spinout Brainomix Takes Total Funding to £18.8 Million in Support of US Expansion

Why It Matters

The investment underscores growing confidence in AI‑enabled diagnostics, accelerating market penetration and potentially improving outcomes for stroke and lung‑fibrosis patients worldwide.

Key Takeaways

• Brainomix total funding reaches £18.8 million
• Series C includes £4.8 million for US growth
• AI platforms target stroke and pulmonary fibrosis care
• Expansion aims to integrate tech in US hospitals
• Funding reflects investor confidence in clinical AI adoption

Pulse Analysis

Brainomix’s latest funding round reflects a broader shift toward AI‑powered imaging solutions in acute care. The company, born out of the University of Oxford, has leveraged its research pedigree to develop two flagship products: Brainomix 360 Stroke, which automates lesion detection and quantifies perfusion metrics, and e‑Lung, an AI‑driven tool that extracts CT biomarkers to track pulmonary fibrosis progression. By securing £18.8 million, Brainomix joins a growing cohort of health‑tech startups attracting venture capital eager to capitalize on the promise of faster, more accurate diagnostics that can be seamlessly embedded into existing radiology pipelines.

The United States represents a strategic frontier for Brainomix, where hospital networks are increasingly allocating budgets to digital transformation and AI adoption. The new capital will fund sales and implementation teams, regulatory navigation, and integration services needed to align the platforms with diverse electronic health‑record systems. Competition is intensifying, with firms like Aidoc and Zebra Medical Vision also courting US health systems, but Brainomix’s focus on both neuro‑vascular and pulmonary indications offers a differentiated portfolio. Successful deployment will hinge on demonstrating measurable improvements in treatment timelines for stroke patients and earlier intervention for fibrotic lung disease, metrics that resonate with payers and clinicians alike.

Beyond the corporate narrative, Brainomix’s raise dovetails with national policy momentum. The UK’s National Cancer Plan and substantial public funding for AI in health signal a supportive ecosystem for innovators. In the US, the FDA’s evolving framework for AI/ML‑based medical devices and the push for real‑world evidence create a fertile environment for scaling. As hospitals seek to reduce diagnostic bottlenecks and enhance patient outcomes, investments like Brainomix’s are likely to accelerate the mainstreaming of AI, reshaping care pathways across specialties.